【摘要】：目的:探討變應(yīng)性鼻炎(AR)患者外周血嗜酸粒細胞(EOS)計數(shù)與IL-33水平的關(guān)系及未經(jīng)任何治療的AR患者(A組)、經(jīng)皮下免疫治療至少1年后AR患者(B組)、經(jīng)皮下免疫治療至少1年后伴變應(yīng)性哮喘(AA)的AR患者(C組)這3組的IL-33水平、嗜酸粒細胞計數(shù)、視覺模擬評分(VAS)的關(guān)系。方法:選取20例健康者作為對照組參與實驗,所有受試者行血細胞分析,統(tǒng)計嗜酸粒細胞數(shù)量。采用酶聯(lián)免疫(ELISA)檢測外周血IL-33水平,所得數(shù)據(jù)用GraphPad.Prism 5.0與SPSS 22.0處理。AR患者行VAS評分并評估鼻部癥狀。結(jié)果:A組IL-33水平高于其他組IL-33水平(P0.05);B組IL-33水平與C組IL-33水平相比,差異無統(tǒng)計學(xué)意義(P0.05);B組和C組IL-33水平均高于對照組IL-33水平(P0.05);A組嗜酸粒細胞計數(shù)高于其他組,各組間相互比較嗜酸粒細胞計數(shù)差異無統(tǒng)計學(xué)意義(P0.05);A組VAS評分高于B組VAS評分(P0.05);A組VAS評分與C組VAS評分比較差異無統(tǒng)計學(xué)意義(P0.05);B組VAS評分與C組VAS評分比較差異無統(tǒng)計學(xué)意義(P0.05)。經(jīng)皮下免疫治療(SCIT)至少1年后AR患者自覺鼻塞、流清涕、打噴嚏等癥狀均有明顯減輕。Spearman檢驗AR患者IL-33水平與嗜酸粒細胞計數(shù)呈弱正相關(guān)(P0.05,r=0.287)。結(jié)論:SCIT對AR療效明顯,可緩解患者臨床癥狀,還可降低患者IL-33水平和外周血嗜酸粒細胞計數(shù)。
[Abstract]:Objective: to investigate the relationship between eosinophil (EOS) count and IL-33 level in peripheral blood of patients with allergic rhinitis (AR) and the patients with AR without any treatment (group A), AR patients (group B) after subcutaneous immunotherapy for at least one year, and subcutaneous immunotherapy. At least a year later, the IL-33 levels in the three groups of AR patients with allergic asthma with (AA) (group C), The relationship between eosinophil count and visual analogue score (VAS). Methods: 20 healthy subjects were selected as control group. All subjects were analyzed with blood cells to count the number of eosinophils. The level of IL-33 in peripheral blood was detected by Elisa (ELISA). The data were treated with GraphPad.Prism 5.0 and SPSS 22.0. VAS score and nasal symptoms were evaluated in AR patients. Results: the level of IL-33 in group A was higher than that in other groups (P0.05 IL-33 level in); B group was higher than IL-33 level in C group (P0.05) IL-33 level in); B group and C group was higher than that in control group (P05); A group was higher than other groups in eosinophil count. There was no significant difference in eosinophil count between each group (P0.05); A group VAS score was higher than B group VAS score (P0.05); A group VAS score and C group VAS score difference was not statistically significant (P0.05); B group VAS score and C group VAS score comparison no significant difference (P0.05). After subcutaneous immunotherapy for at least one year, the symptoms of AR patients such as nasal obstruction, snot and sneezing were significantly alleviated. Spearman test showed a weak positive correlation between IL-33 level and eosinophil count in AR patients (P 0.05 rr 0.287). Conclusion: SCIT is effective in treating AR. It can relieve clinical symptoms, decrease IL-33 level and eosinophil count in peripheral blood.
【作者單位】： 廣西中醫(yī)藥大學(xué)研究生學(xué)院;廣西壯族自治區(qū)人民醫(yī)院耳鼻咽喉科;
【基金】：國家自然科學(xué)基金資助項目(No:81460097) 廣西自然科學(xué)基金(No:2017JJA140333Z) 廣西壯族自治區(qū)衛(wèi)生廳自籌經(jīng)費科研課題(No:Z2016643)
【分類號】：R765.21

【相似文獻】

相關(guān)期刊論文 前5條

1 張克,張志超,彭金娥,孫紅;常年性變應(yīng)性鼻炎鼻腔嗜酸粒細胞及嗜堿性細胞的觀察[J];北京醫(yī)學(xué);1992年04期

2 曹平平;華小陽;劉爭;褚漢啟;崔永華;;CRSsNP中肥大細胞及其與嗜酸粒細胞炎癥的關(guān)系[J];臨床耳鼻咽喉頭頸外科雜志;2010年20期

3 徐明;趙楓;沈安民;周浩杰;;嗜酸粒細胞型鼻息肉患者血清特異性IgE檢測的臨床分析[J];臨床耳鼻咽喉頭頸外科雜志;2012年17期

4 趙長青,陶正德,肖健云,趙素萍,楊平常,孫本韜,喬健天;變應(yīng)性鼻炎鼻粘膜嗜酸粒細胞脫顆粒透射電鏡觀察[J];中華耳鼻咽喉科雜志;1997年02期

5 林欣然;李杰恩;;嗜酸粒細胞在慢性鼻-鼻竇炎發(fā)病機制中的作用[J];醫(yī)學(xué)綜述;2007年14期

相關(guān)博士學(xué)位論文 前1條

1 廖波;TSLP，IL-33及其受體在嗜酸粒細胞性伴有鼻息肉的慢性鼻—鼻竇炎上皮細胞中的相互作用[D];華中科技大學(xué);2015年

相關(guān)碩士學(xué)位論文 前1條

1 楊春;嗜酸粒細胞性慢性鼻-鼻竇炎的分型及臨床特征研究[D];吉林大學(xué);2017年

，

本文編號：2268462